Email Updates

You are here

Home»Resources

Webinar & Meeting Reports

  • New Frontiers in HIV Prevention, Treatment and Cure: An advocate's webinar on passive immunization

    April 21, 2015

    This webinar focused on “passive immunization”—a scientific term for an expanding area of research that’s highly relevant to treatment, prevention and cure work. There are trials in humans happening in many regions of the world—and data are beginning to come in that advocates need to understand, analyze and consider.

    The webinar featured Dr. Sarah Schlesinger (Rockefeller University) who provided an overview of recent developments across the field including new published data.

  • Moving forward with development of GSK1265744 (cabotegravir) for long-acting injectable PrEP in men and women

    April 14, 2015

    In this webinar, Raphael Landovitz, Protocol Chair, presented on HPTN 077—a Phase IIa safety, tolerability and acceptability study of an investigational injectable HIV integrase inhibitor, GSK1265744, for PrEP in HIV uninfected men and women. It is currently enrolling HIV uninfected men and women at low to minimal risk for acquiring HIV infection, ages 18 to 65.

  • MTN 2015 Annual Meeting

    March 13, 2015

    The MTN 2015 Annual Meeting was held at the Bethesda North Marriott Hotel & Conference Center; 5701 Marinelli Road, North Bethesda, MD 20852. The meeting dates were from March 13, 2015 through March 18, 2015. 

  • Demanding Clarity on PrEP: Understanding recent data on oral PrEP

    March 12, 2015

    This webinar featured Jean-Michel Molina of the French research agency ANRS and Sheena McCormack of the UK Medical Research Council discussing the data from the IPERGAY and PROUD studies, respectively. Both trials evaluated oral TDF/FTC (brand name Truvada) as PrEP in gay men and other men who have sex with men, and both reported high levels of protection against HIV acquisition.

  • Follow the Money: Knowns and unknowns when it comes to cash transfers and financial incentives to improve health in people living with and/or at risk of HIV

    March 11, 2015

    This webinar featured Wafaa El-Sadr, principal investigator of HPTN 065, which evaluated the use of cash incentives in improving outcomes for people living with HIV in the United States.

  • After FACTS: What’s next for HIV prevention in women?

    March 9, 2015

    This webinar featured Helen Rees, principal investigator of the FACTS 001 microbicide trial of vaginal 1% tenofovir gel, and Jared Baeten, co-chair of Partners PrEP.

  • CROI 2015

    February 23, 2015 to February 26, 2015

    At the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, new data on oral PrEP and vaginal tenofovir microbicide gel emerged that have implications for HIV prevention worldwide. Read on for a summary of the news.

  • MTN-017: Evolution and Implementation

    February 11, 2015

    IRMA, AVAC and the Microbicide Trials Network (MTN) provided an update on the Phase II safety and acceptability study MTN 017 (now closed to accrual) and looked at potential future directions for rectal microbicide research.

  • NBLCA State of HIV in Black America

    February 6, 2015

    Hosted by the National Black Leadership Commission on AIDS, Inc., in recognition of National African American HIV/AIDS Awareness Day, as a community forum engaged discussion on the Intersection of Health, Education & Community in the fight to End AIDS.

  • Global launch of the G-FINDER 2014 Reproductive Health report

    February 5, 2015

    Report co-author, Dr Mary Moran, and international key commentators discussed the report's findings and health funding decisions for the future. The first G-FINDER Reproductive Health survey reported on 2013 global investment into research and development (R&D) for new reproductive health products for developing countries. It covered investment for post-partum haemorrhage, contraceptives, non-HIV STIs, multipurpose prevention technologies and platform technologies.

Pages